NCT00290810View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

August 31, 2010

Conditions
B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

bevacizumab

Given IV

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00290810 - Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter